Aska Of Japan, Actavis Of Iceland To Form Generics Venture
This article was originally published in PharmAsia News
Japan's Aska Pharmaceutical and Iceland's Actavis Group plan a joint venture next year to develop and market generic drugs. The deal, expected to take effect next April in Japan, would give Aska a 55 percent stake and Actavis the rest. Under the plan, Aska would draw on Actavis-produced raw materials to produce drugs in Japanese facilities, with expectations their first co-developed drugs would reach the market in 2010. Actavis has a pipeline of about 1,000 drugs, but the joint venture expects to produce only about seven a year. (Click here for more - a subscription may be required
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.
From the rise of DTC to the shadow of Caronia, Abrams, the long-time head of the Office of Prescription Drug Promotion, monitored dramatic changes in the pharmaceutical marketplace and regulatory environment. He retired from FDA on 23 October after a tenure marked as much by careful research projects and copious guidances as it was by promotional and legal upheavals.